Table 2.
Association between JPH3 protein expression and clinicopathological parameters in 192 primary gastric tumor cases
| Clinicopathological parameters | n | JPH3 protein expression | P-value | |
|---|---|---|---|---|
| Low expression n=116 (60.4%) | High expression n=76 (39.6%) | |||
| Sex | ||||
| Male | 138 | 83 (60.1%) | 55 (39.9%) | |
| Female | 54 | 33 (61.1%) | 21 (38.9%) | 0.946 |
| Age | ||||
| >62 | 95 | 57 (60%) | 38 (40%) | |
| ≤62 | 97 | 59 (60.8%) | 38 (39.2%) | 0.907 |
| Differentiation | ||||
| Well and Moderate | 75 | 33 (44%) | 42 (56%) | |
| Poor | 117 | 83 (70.9%) | 34 (29.1%) | 0.000 |
| Clinical stage | ||||
| I | 43 | 21 (48.8%) | 22 (51.2%) | |
| II | 40 | 18 (45%) | 22 (55%) | |
| III | 76 | 52 (68.4%) | 24 (31.6%) | |
| IV | 33 | 25 (75.8%) | 8 (24.2%) | 0.018 |
| Lymph node metastasis | ||||
| Absent | 86 | 43 (50%) | 43 (50%) | |
| Present | 106 | 73 (68.9%) | 33 (31.1%) | 0.008 |
| Liver metastasis | ||||
| Absent | 157 | 89 (56.7%) | 68 (43.3%) | |
| Present | 35 | 27 (77.1%) | 8 (22.9%) | 0.025 |
| Invasion | ||||
| T1-2 | 62 | 30 (48.4%) | 32 (51.6%) | |
| T3-4 | 130 | 86 (66.2%) | 44 (33.8%) | 0.019 |